MO
Therapeutic Areas
Sagimet Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Denifanstat | Metabolic Dysfunction-Associated Steatohepatitis (MASH) with F2/F3 fibrosis | Phase 3-ready |
| Denifanstat (ASC40) | Moderate to Severe Acne Vulgaris | Phase 3 |
| Denifanstat / Resmetirom | MASH (implied) | Phase 2 |
| TVB-3567 | Acne | Phase 1 |
Leadership Team at Sagimet Biosciences
DH
David Happel
Chief Executive Officer & Director
EB
Eduardo Bruno Martins
Chief Medical Officer
TC
Thierry Chauche
Chief Financial Officer
GK
George Kemble
Chair of the Board
AP
Anne Phillips
Board Director
BS
Beth Seidenberg
Lead Independent Director